Neurology

The future of Alzheimer's
Special Report

Forecasting Alzheimer’s: With a tsunami of new diagnoses expected, experts calculate the best ways to shift the tide

By Sharon Begley

Vertex Pharmaceuticals Inc. building
Biotech

Vertex takes on Huntington’s disease in deal with Ribometrix

By Jonathan Saltzman — Boston Globe

High school football team
First Opinion

Is football bad for the brain? We know little about the long-term effects of concussions

By Munro Cullum

Margaret Arach
Health

A devastating illness rocked Uganda, then disappeared. Disabled children — and a mystery — remain

By Jacquelyn Corley

MS medication
Pharmalot

Price hikes for multiple sclerosis drugs helped Medicare Part D out-of-pocket costs to skyrocket

By Ed Silverman

Silhouetted NFL players
Health

Former NFL players with worse or more frequent concussions are more likely to show sexual dysfunction, study shows   

By Lev Facher

CT scan
Health Tech

With brain trauma, surgeons don’t always know if an operation will help. Could AI change that?

By Jacquelyn Corley

Alzheimer's Iowa state fair
Politics

Alzheimer’s advocates are swarming the Iowa State Fair, pushing politicians to consider policies to fight the disease 

By Nicholas Florko

In the Lab

The entire human brain in ‘unprecedented’ detail, thanks to powerful MRI

By Sharon Begley

Gingipains in the brain
Biotech

An old idea that’s gaining new traction: curing Alzheimer’s by targeting gum-disease bacteria

By Sharon Begley

Dr. Ronny Jackson
Health

Worries about accuracy of widely used dementia test prompt training requirement

By JoNel Aleccia — Kaiser Health News

Hippocampus & Alzheimer's
In the Lab

Role of seizures in Alzheimer’s disease is gaining overdue attention

By Lauren Aguirre

Play
The Readout LOUD

Listen: Elon Musk’s monkey cyborg, Gilead’s shifting future, & an app for anxiety

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Memory loss illustration
Health

LGBT people more likely than counterparts to report memory problems, survey finds

By Diana Cai

Jeremy Levin
Biotech

Bruised by Wall Street, Ovid Therapeutics may be one step closer to vindication with rare disease drug

By Damian Garde

Biotech

The wait just got longer to see Biogen’s data on its failed Alzheimer’s treatment

By Damian Garde

Alzheimer's research
Special Report

The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades

By Sharon Begley

Enterovirus D-68
Health

New evidence points to possible cause of puzzling paralysis in kids

By Maggie Fox

Football 1961
Health

Former NFL players die at a faster rate than other professional athletes, study finds

By Shraddha Chakradhar

Brain cancer
Biotech

Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

By Adam Feuerstein

brainHQ training screenshot
Health

Brain training shows promise as a treatment for veterans’ cognitive problems after TBI

By Sharon Begley

Mouse Brain colorized
In the Lab

By disabling a protein in the brain’s blood vessels, researchers ease age-related deterioration in mice

By Andrew Joseph

Spinraza injection
Biotech

Your guide to the mounting competition among new SMA drugs

By Damian Garde and Adam Feuerstein

Pharmalot

Pharmalittle: Pfizer prices new rare disease drug at $225,000; Novartis pushes gene therapy

By Ed Silverman

Cytokinetics
Biotech

Cytokinetics pushes ahead with ALS drug despite negative clinical trial outcome

By Adam Feuerstein

Jackson Moore
Biotech

Scientists see hope in a rare disease drug Wall Street has all but written off

By Damian Garde

MS medication
Pharmalot

To the moon: Out-of-pocket costs for multiple sclerosis medicines have skyrocketed

By Ed Silverman

FDA room
Pharmalot

Advocacy group sues FDA for failing to issue warnings on Parkinson’s drugs about compulsive behaviors

By Ed Silverman

Neurons
Biotech

For Dan Doctoroff, funding ALS research is a family matter

By Jonathan Saltzman — Boston Globe

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy